KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Debt: 2024-2025

Historic Non-Current Debt for Esperion Therapeutics (ESPR) over the last 1 years, with Sep 2025 value amounting to $151.7 million.

  • Esperion Therapeutics' Non-Current Debt was N/A to $151.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year change of. This contributed to the annual value of $141.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Non-Current Debt is $151.7 million, which was up 3.55% from $146.5 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Non-Current Debt registered a high of $151.7 million during Q3 2025, and its lowest value of $141.0 million during Q4 2024.
  • In the last 2 years, Esperion Therapeutics' Non-Current Debt had a median value of $144.0 million in 2025 and averaged $145.1 million.